Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors

Figures & data

Table 1. Demographics and clinical characteristics of the study population with chronic myelogenous leukemia.

	n (n = 2,005)^a	%
Age (years)
Mean (SD)	56.3 (14.7)
Median	56.0
Charlson Comorbidity Index (CCI)
Mean (SD)	2.9 (1.5)
Median	2.0
Age group
18–34 years	146	7.3
35–54 years	739	36.8
55–74 years	846	42.2
≥75 years	274	13.6
CCI Group
CCI = 1–2	1,185	59.1
CCI = 3–4	597	29.8
CCI ≥5	223	11.1
Gender
Male	1,116	55.7
Female	889	44.3
Region
South	754	37.6
North Central	586	29.2
West	338	16.9
Northeast	301	15.0
Health plan type
Preferred Provider Organization	1,140	56.9
Health Maintenance Organization	298	14.9
Comprehensive	275	13.7
Point-of-Service (POS)	143	7.1
Consumer Driven Health Plan	51	2.5
Exclusive Provider Organization	21	1.1
POS w/Capitation	4	0.2

^a 2,005 patient years of follow-up.

SD: standard deviation.

Figure 1. Mean number of hospitalizations and length of stay (LOS) per patient for patients with select adverse events. FAS: femoral arterial stenosis; PAOD: peripheral arterial occlusive disease; Inter Claud: intermittent claudication; CAS: coronary artery stenosis; Peri Eff: pericardial effusion; Pleu Eff: pleural effusion; CH: conjunctival hemorrhage; LOS: length of stay.

Table 2. Adverse event-related healthcare resource utilization and associated costs among patients with the corresponding select adverse events from the study population with chronic myelogenous leukemia

Adverse event	Healthcare resource utilization or cost, Mean (SD)
Femoral arterial stenosis (n^a)	12
Inpatient
Number of hospitalizations	0.08 (0.29)
Total length of hospital stay (days)	3.00 (10.39)
Total hospital cost	$16,800 ($58,196)
Outpatient
Number of claims	2.00 (1.35)
Total outpatient claims cost	$215 ($244)
Total medical cost	$17,015 ($58,129)
Peripheral arterial occlusive disease (n)	38
Inpatient
Number of hospitalizations	0.24 (0.49)
Total length of hospital stay (days)	2.16 (6.66)
Total hospital cost	$14,263 ($40,919)
Outpatient
Number of claims	5.03 (8.77)
Total outpatient claims cost	$891 ($1,271)
Total medical cost	$15,154 ($40,789)
Intermittent claudication (n)	23
Inpatient
Number of hospitalizations	0.04 (0.21)
Total length of hospital stay (days)	0.09 (0.42)
Total hospital cost	$5,164 ($24,768)
Outpatient
Number of claims	4.43 (7.05)
Total outpatient claims cost	$947 ($1,400)
Total medical cost	$6,112 ($24,600)
Coronary artery stenosis (n)	237
Inpatient
Number of hospitalizations	0.09 (0.36)
Total length of hospital stay (days)	0.33 (1.49)
Total hospital cost	$3,083 ($15,614)
Outpatient
Number of claims	6.69 (10.49)
Total outpatient claims cost	$1,861 ($6,333)
Total medical cost	$4,944 ($17,578)
Pericardial effusion (n)	13
Inpatient
Number of hospitalizations	0.15 (0.38)
Total length of hospital stay (days)	0.62 (1.71)
Total hospital cost	$2,049 ($5,163)
Outpatient
Number of claims	10.00 (17.57)
Total outpatient claims cost	$748 ($1,207)
Total medical cost	$2,797 ($5,879)
Pleural effusion (n)	94
Inpatient
Number of hospitalizations	0.07 (0.26)
Total length of hospital stay (days)	0.26 (1.18)
Total hospital cost	$1,018 ($3,954)
Outpatient
Number of claims	8.47 (12.05)
Total outpatient claims cost	$890 ($1,528)
Total medical cost	$1,908 ($4,548)
Conjunctival hemorrhage (n)	44
Inpatient
Number of hospitalizations	0
Total length of hospital stay (days)	0
Total hospital cost	0
Outpatient
Number of claims	1.66 (1.27)
Total outpatient claims cost	$134 ($104)
Total medical cost	$134 ($104)

^a n refers to the total number of patients with the selected adverse events during the 12-month follow-up period.

SD: standard deviation.

Figure 2. Total mean medical and inpatient and outpatient costs per patient for patients with select adverse events. FAS: femoral arterial stenosis; PAOD: peripheral arterial occlusive disease; Inter Claud: intermittent claudication; CAS: coronary artery stenosis; Peri Eff: pericardial effusion; Pleu Eff: pleural effusion; CH: conjunctival hemorrhage.